Wong GLH, et al. - In 2000-2017, researchers identified the prevalence of key co-morbidities and concomitant medications in a territory-wide chronic hepatitis B (CHB) cohort in Hong Kong. Participants in the study were 135,395 CHB patients. The demographics and prevalence of key co-morbidities, including diabetes mellitus, hypertension, chronic kidney disease, osteopenia/osteoporosis based on diagnosis codes, relevant medications and/or laboratory parameters were determined in 4 time periods according to the first appearance of CHB patients: 2000-2004, 2005-2009, 2010-2013 and 2014-2017. Data reported that there has been a trend of increasing prevalence of several common co-morbidities over the 4 periods: hypertension 25.5%, 23.8%, 27.2% and 28.6%; diabetes mellitus 10.6%, 12.5%, 16.1% and 20.1%; cardiovascular disease 12.5%, 16.9%, 20.9% and 22.2%, and malignancy 7.0%, 13.2%, 17.3% and 23.6%, respectively. With the increasing prevalence of common co-morbidities, CHB patients are getting older. When selecting antiviral therapy, these co-morbidities should be considered.